tbuckley/cabot-search huggingface dataset:
In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia.
Authors: Jianhua Yu, Li Yu, Bjoern Hackanson, Min Wei, Zachary Boyd, Akihiko Yokohama, Chunhui Liu, Rossana Trotta, Hsiaoyin C. Mao, Brian Becknell, Michael S. Jaung, Shujun Liu, John C. Byrd, Guido Marcucci, Christoph Plass, Michael A. Caligiuri
Journal: Blood (2006)
Optimal management of leptomeningeal carcinomatosis in breast cancer patients - a systematic review.
Authors: Shaan Dudani, Sasha Mazzarello, John Frederick Hilton, Brian Hutton, Lisa Vandermeer, Ricardo Fernandes, Mohammed FK Ibrahim, Stephanie Smith, Khalid Salim Al-Baimani, Jean-Michel Caudrelier, Risa Shorr, Mark J. Clemons
Journal: Journal of Clinical Oncology (2016)

e13526 Background: The incidence of leptomeningeal carcinomatosis (LC) in breast cancer patients (LC-BC) is rising. Despite significantly impacting patient survival and quality of life (QoL), little is known about its optimal management. A systematic review of treatment strategies for LC-BC was performed. Methods: EMBASE, Ovid Medline(R), Pubmed, and the Cochrane Central Register of Controlled Trials were searched from 1946 to September 2015 for trials reporting on treatments for LC-BC. All treatment modalities were considered. Outcome measures of interest included: overall survival (OS), time to neurologic progression (TTNP), QoL and treatment toxicity. Results: Of 724 unique citations, 181 studies met the pre-specified eligibility criteria. Most studies were not specific to LC-BC patients. Of four identified randomized controlled trials, one was specific to LC-BC patients and compared standard systemic therapy and involved field radiotherapy +/- intrathecal (IT) methotrexate (35 patients), while the remaining three compared different IT chemotherapy regimens (157 total patients, 58 with LC-BC). Of the remaining studies, 19 were non-randomized, interventional studies (225 LC-BC patients); 156 were observational studies (3438 LC-BC patients); and 2 were systematic reviews (17 LC-BC patients). There was minimal prospective data available on OS, TTNP, QoL, or toxicity. Due to study heterogeneity, a meta-analysis was not performed. Conclusions: Minimal high-quality evidence exists regarding optimal treatment of LC-BC. Identified studies were heterogeneous in nature and often methodologically poor. With no established standard of care, a wide variety of treatment strategies are employed worldwide, with no data to support any one therapeutic approach over another. The only RCT that specifically assessed IT chemotherapy in the presence of standard systemic and radiation therapy showed no benefit and, if anything, harm. If the management of these patients is to be improved, further prospective, tumour-specific trials are urgently needed with improved inter-study methodological consistency and appropriately reported data on OS, TTNP, QoL and toxicity.
Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.
Authors: Steven P. Treon, Jacob D. Soumerai, Christopher J. Patterson, Zachary R. Hunter, Rose Villarreal, Irene M. Ghobrial
Journal: Blood (2006)
P1311 : Thril; pilot study evaluating the safety and efficacy profile of regulatory T cell therapy in liver transplant recipients
Authors: G.P. Whitehouse, N. Safinia, I. Rebollo-Mesa, K. Lowe, S. Thirkell, L. Fry, A. Androulidakis, M. Martinez-Llordella, A. Hope, V. Aluvihare, C. Fisher, R. Lechler, N. Heaton, G. Lombardi, A. Sanchez-Fueyo
Journal: Journal of Hepatology (2015)
Incidence Rate of Breast Cancer in Young Women
Authors: Mark R. Goldstein, Luca Mascitelli
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI
Authors: Gennaro Giustino, Alaide Chieffo, Tullio Palmerini, Marco Valgimigli, Fausto Feres, Alexandre Abizaid, Ricardo A. Costa, Myeong-Ki Hong, Byeong-Keuk Kim, Yangsoo Jang, Hyo-Soo Kim, Kyung Woo Park, Martine Gilard, Marie-Claude Morice, Fadi Sawaya, Gennaro Sardella, Philippe Genereux, Bjorn Redfors, Martin B. Leon, Deepak L. Bhatt, Gregg W. Stone, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
Telomere Shortening At Diagnosis Of Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Is Significantly More Pronounced In Patients With Less-Than-Optimal Versus Optimal Molecular Response (ELN criteria) After 12 Months Of Treatment With Nilotinib
Authors: Katrin Wenn, Lena Tomala, Fabian Beier, Stefan Wilop, Lucia Vankann, Christian Hasenbank, Oliver Frank, Claudia Walasek, Andreas Hochhaus, Frank Giles, Steffen Koschmieder, Patrick Ziegler, Tim H. Brümmendorf
Journal: Blood (2013)
Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States
Authors: B.J. Metcalf, S. Chochua, R.E. Gertz, Z. Li, H. Walker, T. Tran, P.A. Hawkins, A. Glennen, R. Lynfield, Y. Li, L. McGee, B. Beall, A. Reingold, S. Brooks, H. Randel, L. Miller, B. White, D. Aragon, M. Barnes, J. Sadlowski, S. Petit, M. Cartter, C. Marquez, M. Wilson, M. Farley, S. Thomas, A. Tunali, W. Baughman, L. Harrison, J. Benton, T. Carter, R. Hollick, K. Holmes, A. Riner, C. Holtzman, R. Danila, K. MacInnes, K. Scherzinger, K. Angeles, J. Bareta, L. Butler, S. Khanlian, R. Mansmann, M. Nichols, N. Bennett, S. Zansky, S. Currenti, S. McGuire, A. Thomas, M. Schmidt, J. Thompson, T. Poissant, W. Schaffner, B. Barnes, K. Leib, K. Dyer, L. McKnight, R. Gierke, O. Almendares, J. Hudson, L. McGlone, G. Langley
Journal: Clinical Microbiology and Infection (2016)

Our whole genome sequence (WGS) pipeline was assessed for accurate prediction of antimicrobial phenotypes. For 2316 invasive pneumococcal isolates recovered during 2015 we compared WGS pipeline data to broth dilution testing (BDT) for 18 antimicrobials. For 11 antimicrobials categorical discrepancies were assigned when WGS-predicted MICs and BDT MICs predicted different categorizations for susceptibility, intermediate resistance or resistance, ranging from 0.9% (tetracycline) to 2.9% (amoxicillin). For β-lactam antibiotics, the occurrence of at least four-fold differences in MIC ranged from 0.2% (meropenem) to 1.0% (penicillin), although phenotypic retesting resolved 25%-78% of these discrepancies. Non-susceptibility to penicillin, predicted by penicillin-binding protein types, was 2.7% (non-meningitis criteria) and 23.8% (meningitis criteria). Other common resistance determinants included mef (475 isolates), ermB (191 isolates), ermB + mef (48 isolates), tetM (261 isolates) and cat (51 isolates). Additional accessory resistance genes (tetS, tet32, aphA-3, sat4) were rarely detected (one to three isolates). Rare core genome mutations conferring erythromycin-resistance included a two-codon rplD insertion (rplD69-KG-70) and the 23S rRNA A2061G substitution (six isolates). Intermediate cotrimoxazole-resistance was associated with one or two codon insertions within folP (238 isolates) or the folA I100L substitution (38 isolates), whereas full cotrimoxazole-resistance was attributed to alterations in both genes (172 isolates). The two levofloxacin-resistant isolates contained parC and/or gyrA mutations. Of 11 remaining isolates with moderately elevated MICs to both ciprofloxacin and levofloxacin, seven contained parC or gyrA mutations. The two rifampin-resistant isolates contained rpoB mutations. WGS-based antimicrobial phenotype prediction was an informative alternative to BDT for invasive pneumococci.
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
Authors: Wendy Béguelin, Matt Teater, Micah D. Gearhart, María Teresa Calvo Fernández, Rebecca L. Goldstein, Mariano G. Cárdenas, Katerina Hatzi, Monica Rosen, Hao Shen, Connie M. Corcoran, Michelle Y. Hamline, Randy D. Gascoyne, Ross L. Levine, Omar Abdel-Wahab, Jonathan D. Licht, Rita Shaknovich, Olivier Elemento, Vivian J. Bardwell, Ari M. Melnick
Journal: Cancer Cell (2016)
Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD
Authors: Sabela Carballal, Sandra Maisterra, Antonio López-Serrano, Antonio Z Gimeno-García, María Isabel Vera, José Carlos Marín-Garbriel, José Díaz-Tasende, Lucía Márquez, Marco Antonio Álvarez, Luis Hernández, Luisa De Castro, Jordi Gordillo, Ignasi Puig, Pablo Vega, Marco Bustamante-Balén, Juan Acevedo, Beatriz Peñas, María López-Cerón, Elena Ricart, Miriam Cuatrecasas, Mireya Jimeno, María Pellisé
Journal: Gut (2016)

Objective Outside clinical trials, the effectiveness of chromoendoscopy (CE) for long-standing IBD surveillance is controversial. We aimed to assess the effectiveness of CE for neoplasia detection and characterisation, in real-life. Design From June 2012 to 2014, patients with IBD were prospectively included in a multicentre cohort study. Each colonic segment was evaluated with white light followed by 0.4% indigo carmine CE. Specific lesions' features were recorded. Optical diagnosis was assessed. Dysplasia detection rate between expert and non-expert endoscopists and learning curve were ascertained. Results Ninety-four (15.7%) dysplastic (1 cancer, 5 high-grade dysplasia, 88 low-grade dysplasia) and 503 (84.3%) non-dysplastic lesions were detected in 350 patients (47% female; mean disease duration: 17 years). Colonoscopies were performed with standard definition (41.5%) or high definition (58.5%). Dysplasia miss rate with white light was 40/94 (57.4% incremental yield for CE). CE-incremental detection yield for dysplasia was comparable between standard definition and high definition (51.5% vs 52.3%, p=0.30). Dysplasia detection rate was comparable between expert and non-expert (18.5% vs 13.1%, p=0.20). No significant learning curve was observed (8.2% vs 14.2%, p=0.46). Sensitivity, specificity, and positive and negative predictive values for dysplasia optical diagnosis were 70%, 90%, 58% and 94%, respectively. Endoscopic characteristics predictive of dysplasia were: proximal location, loss of innominate lines, polypoid morphology and Kudo pit pattern III–V. Conclusions CE presents a high diagnostic yield for neoplasia detection, irrespectively of the technology and experience available in any centre. In vivo, CE optical diagnosis is highly accurate for ruling out dysplasia, especially in expert hands. Lesion characteristics can aid the endoscopist for in situ therapeutic decisions. Trial registration number NCT02543762.
German body calls for pause in European plan for fast track drug approval
Authors: Nigel Hawkes
Journal: BMJ (2016)

Plans by the European Medicines Agency to expand its fast track approach to approving new drugs have provoked a tough response from an influential German body, the Institute for Quality and Efficiency in Healthcare (IQWiG).

In a commentary published on 12 August IQWiG said that the plan was vague and failed to provide sufficient reassurance that drugs approved under the fast track approach would be safe and effective.1 It called for the scheme to be paused.

Earlier this month the EMA published the final report on its pilot scheme, claiming that its fast track approach would provide important benefits as long as the right drugs were chosen and all interested parties were consulted.2 But …
Use of Administrative Data for Public Reporting of Outcomes—Reply
Authors: Steven A. Farmer, Bernard S. Black, Robert O. Bonow
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective evaluation of whole-body cancer screening with multiple modalities including FDG-PET: Results from annual screening for 5 years in 1,197 healthy volunteers.
Authors: S. Nishizawa, H. Kodama, Y. Maeda, H. Okada, S. Kojima, S. Teramukai, M. Fukushima
Journal: Journal of Clinical Oncology (2010)

1517 Background: We started a prospective cohort study in August 2003 to evaluate the utility of whole- body cancer screening with multiple modalities including positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in a healthy population. Methods: A total of 1,197 healthy volunteers age 35 or older (46.7 ± 7.7 y.o.) were enrolled between August 2003 and July 2004 and offered annual cancer screening for 5 years (screening phase) with subsequent long-term follow-up. Screening modalities included were whole-body FDG-PET, abdominal and chest computed tomography, brain and pelvic magnetic resonance imaging, several tumor markers, and fecal occult blood testing. Results: The screening phase ended in June 2009. Of the 1,197 subjects, 1,025 completed the screening five times, while 53, 46, 38, and 35 completed four, three, two, and one screenings, respectively. As of the end of December 2009, a total of 35 cancers (2.9% of 1197) were confirmed. Twenty-seven of the 35 (77.1%) were detected by screening. FDG-PET was positive in 15 (42.9%). Twenty of the 27 showed positive findings in the initial screening. Fifteen incident cancers were observed. Of the 15, seven were detected by the subsequent annual screening (1, 0, 5, and 1 in the second, third, fourth, and fifth screening, respectively), but eight were not detected by screening and were diagnosed after developing symptoms (2, 1, 3, and 2 before the second, third, forth, and fifth screening, respectively). Four of the 8 were progressive diseases and 3 of the 4 died of cancer. One of the 7 with incident cancers detected by the screening also died of cancer. Others live well without recurrence. Positive predictive values were 7.5% (20/267) and 1.9% (7/363) for the initial and subsequent screening, respectively. Conclusions: While whole-body cancer screening has initial performance supporting possible utility, the results do not support annual screening; screening every three years would not affect outcome in this working-age population. Stages of cancers I II III IV N.A. Total Initial screening 12 2 4 0 2 20 Subsequent screening 3 3 0 1* 7 Not detected 3 1 1 2* 1* 8 * Patient died. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Hamamatsu Photonics KK Hamamatsu Photonics KK
An injectable acellular matrix scaffold with absorbable permeable nanoparticles improves the therapeutic effects of docetaxel on glioblastoma
Authors: He-Lin Xu, Kai-Li Mao, Cui-Tao Lu, Zi-Liang Fan, Jing-Jing Yang, Jie Xu, Pian-Pian Chen, De-Li ZhuGe, Bi-Xin Shen, Bing-Hui Jin, Jian Xiao, Ying-Zheng Zhao
Journal: Biomaterials (2016)
Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT II
Authors: Gary S. Francis, Jay N. Cohn, Gary Johnson, Thomas S. Rector, Steven Goldman, Ada Simon
Journal: Circulation (1993)

Background. Congestive heart failure is a clinical syndrome characterized by neuroendocrine activation. Measurements of plasma norepinephrine and plasma renin activity were performed in the Vasodilator-Heart Failure Trial II (V-HeFT II) to characterize the effects of therapy on neuroendocrine activation and to examine the responses to therapy among patients with different degrees of activation. Methods and Results. The baseline median plasma norepinephrine value (n=743) was 490 pg/mL and the baseline median plasma renin activity (n=737) was 6.9 ng.mL -1 .hr -1 . Baseline plasma renin activity and plasma norepinephrine correlated poorly with each other (r=0.12), implying that these two neuroendocrine systems are being activated by separate processes
Unintended Consequences of Current Breastfeeding Initiatives
Authors: Joel L. Bass, Tina Gartley, Ronald Kleinman
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Human and ant social behavior should be compared in a very careful way to draw valid parallels
Authors: Ewa Joanna Godzińska
Journal: Behavioral and Brain Sciences (2016)

Abstract Gowdy &amp; Krall provide an interesting discussion of evolutionary origins and consequences of ultrasociality. However, some of their statements concerning various features of ant and human social behavior do not adequately reflect present knowledge about the discussed issues, which include, among others, polyethism, cultural information transfer, within-group conflicts and resistance in ant societies, and reproductive division of labor in humans. Gowdy &amp; Krall (G&amp;K) provide an interesting discussion of evolutionary origins and consequences of ultrasociality, an advanced form of social behavior that evolved independently in both social insects and humans. Their reflections are thought-provoking, but some statements concerning various features of ant and human social behavior do not reflect adequately the present knowledge about the discussed issues.
Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC).
Authors: D. Ksienski, S. Gill
Journal: Journal of Clinical Oncology (2010)

6033 Background: Evidence-based guidelines consistently recommend AT for stage III CC but AT is not routinely recommended for stage II CC. Actual practice of the evidence varies. The aim of this retrospective study was to identify patient, tumour-specific and temporal factors associated with receipt of AT for stage II CC and exclusion of AT for stage III CC. Methods: Charts were reviewed for pts with resected stage II (n = 350) and III CC (n = 398) referred to the British Columbia Cancer Agency in 2004 and 2006. Two-tailed Fisher's exact test was used to assess statistical significance (p < 0.05). Results: In stage II pts, 21% (n = 72) received AT. Fewer pts received AT in 2006 compared to 2004 (16% vs. 28% p = 0.015). Compared to untreated pts, stage II pts who received AT were significantly more often younger than 70y (81% vs. 54%), married (89% vs. 85%), had less than 12 lymph nodes sampled (54% vs. 46%), vascular invasion (25% vs. 6%), and high grade (28% vs. 12%). Gender, ethnicity, residence, high CEA, and T4 were not associated with AT in stage II. The reason for AT use stated in the consult note: T4 29%, other high-risk feature 51%, pt request 10%, not specified 10%. In stage III pts, 25% (n = 99) did not receive AT. Compared to treated pts, stage III pts who did not receive AT were significantly more often 70y and older (76% vs. 34%) and saw an oncologist more than 42 days after surgery (13% vs. 28%). Gender, ethnicity, residence, grade, lymphovascular invasion, and T4 or N2 status were not associated with no AT in stage III. The reason for no AT stated in the consult note: pt decline 34%, comorbidity 33%, advanced age 22%, delayed presentation 3%, not specified 8%. Conclusions: Receipt of AT in stage II was associated with younger age, marital status, node retrieval, grade and vascular invasion. The use of AT in stage II decreased over time. For stage III, older age and delayed presentation were associated with failure to receive AT. Pt decline was the most commonly cited reason for no AT in stage III. These data highlight the interplay between patient and tumour factors which impact upon AT decision-making beyond stage of disease alone. No significant financial relationships to disclose.
Incidental Finding of Cerebellar Medulloblastoma on 68Ga-DOTATATE PET/CT in a Patient With Appendiceal Carcinoid
Authors: Mico Chan, Edward Hsiao
Journal: Clinical Nuclear Medicine (2016)

68Ga-DOTATATE PET/CT is increasingly used to image somatostatin receptor expressing tumors. Various intracranial tumors including medulloblastoma are known to express somatostatin receptors. We present a case of incidental cerebellar medulloblastoma on a staging 68Ga-DOTATATE PET/CT for appendiceal carcinoid.